Silence Therapeutics provides SLN360 & SLN124 clinical program updates

LONDON, January 12, 2023–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today provided the following SLN360 and SLN124 program updates during a presentation at the 41st Annual J.P. Morgan Healthcare Conference

SLN360 for heart disease

  • In the SLN360 Phase 2 study in high risk atherosclerotic heart disease (“ASCVD”), the first subjects were enrolled. The Company intends to complete enrollment in this study by the fourth-quarter of 2023. Further information can be found about the trial here.

  • Silence is expecting data from the ongoing phase 1 multi-dosage study with subjects with high lipoprotein (a) and stable ASCVD, which will be completed in the fourth quarter 2023. Participants receiving SLN360 in 300 mg or 600 mg doses saw median Lp (a) reductions of 96% to 98% in the single dose study evaluating healthy volunteers.

SLN124 is for hematological disorders

  • Participation in the SLN124 Phase 1/2 Study in Polycythemia Vera (“PV”) is possible at all locations. The SLN124 PV Study is a two-part trial that includes a Phase 1 open-label, dose-finding study, followed by a Phase 2 randomized, doubleblind, placebo controlled parallel arm study. You can find more information about the trial here here.

  • Silence is expecting data from the ongoing phase 1 multiple-dose study of SLN124 for thalassemia patients during the fourth quarter of 2023.

Craig Tooman (President and CEO of Silence) stated, “2023 looks poised to become an important and exciting Year for Silence.” “We were happy to start dosing in SLN360 phase II ASCVD and are excited by the enthusiasm for the program. We have also started the SLN124 PV research and we look forward to sharing more updates as the program develops this year. We remain very pleased with the prospects for our mRNAi GOLD™ platform.”

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence is also involved in ongoing research and development collaborations including AstraZeneca. Mallinckrodt Pharmaceuticals. Hansoh Pharma. Please visit www.silence.com to find out more. https://www.silence-therapeutics.com/.

Forward-Looking Statements

This announcement contains forward-looking statements that are within the scope of U.S. securities laws. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s clinical and commercial prospects, regulatory approvals of the Company’s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company’s clinical trials and the anticipated timing or outcomes of data reports from the Company’s clinical trials. These forward-looking statements do not reflect historical facts, but are based upon the Company’s current assumptions and beliefs, expectations, projections, estimates, and projections regarding its industry. Forward-looking statements are identified by the use of words like ‘anticipates’, ‘expects’, ‘intends’, ‘plans’, ‘believes’, seeks’, & ‘estimates’ and similar expressions. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company’s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2022. These forward-looking statements are only indicative of the Company’s view as of the date this announcement was made. Security holders and potential security holders should not place undue trust in them. These forward-looking statements only reflect events as they occur on the date of this announcement. Except as required or permitted by law or any regulatory authority, the Company is not obligated to make public any revisions or updates of these forward-looking statement to reflect unanticipated or unexpected events.

Businesswire.com – View the source version https://www.businesswire.com/news/home/20230112005311/en/

Contacts

Enquiries:
Silence Therapeutics plc
Gem Hopkins, Head IR and Corporate Communications
[email protected]
Tel: +1 (646) 637-3208

Previous post Why a rising act is limiting gig prices
Next post Tesla significantly lowers EV price in Europe and the US